What OrganaBio’s Excellos asset acquisition reveals about next-generation CDMO demand
Cell therapy needs redundancy, not just cleanrooms. OrganaBio’s Excellos deal tests whether bicoastal CDMO scale can reduce developer risk.
Pharma & Biotech
Pharma & Biotech
How OrganaBio’s RxMP partnership could advance RMP-402 for severe bleeding control
Find out how OrganaBio’s RxMP partnership could advance RMP-402, a first-in-class therapy for severe bleeding control.